Company intelligence
HC Andersen Capital
For Investors: News, Research and Events on Scandinavian equities: inderes.dk
About HC Andersen Capital
HC ANDERSEN CAPITAL is a Democratic platform (IRaaS) that connects investors with Scandinavian companies. HC Andersen Capital receives payment from the companies we mention for a Digital IR/Corporate Visibility subscription agreement. This is not a piece of advice to buy, not to buy, sell, or not to sell shares.
Verified activity
Signals from HC Andersen Capital
21 published signals
Presence & Recognition
HC Andersen Capital notes that Gubra hosts its R&D Event in London on 27 October, where the UCN2 development strategy, indication expansion, and the 2030 growth strategy are expected to be set out.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital updated its One-pager investment case on Gubra to reflect a quarter in which clinical picture changed materially, with both partnered obesity assets moving into Phase 2 and the GUB-UCN2 programme mechanism validated by a large pharma transaction.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital notes that the next twelve months carry several distinct triggers, including AbbVie presenting the full ABBV-295 Phase 1 MAD dataset at EASD on 30 September, followed by topline from the ongoing Phase 1b study in obese patients.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital notes that first single ascending dose data from GUB-UCN2 follow in H1 2027, on broadly the same timeline as Hanmi's Phase 1 completion.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital notes that Genentech (Roche) licensed Hanmi's HM17321, a Phase 1 UCN2 analogue targeting the same CRHR2 mechanism as GUB-UCN2, for USD 190m upfront and up to USD 2.3bn in total value, with Genentech/Roche taking over development from Phase 2.
Reported by HC Andersen Capital
Research & Knowledge
HC Andersen Capital reported that Flügger group A/S ventes at offentliggøre its quarterly financial statements for the first half of 2026/27 covering the period from 1 May to 31 July 2026.
Reported by HC Andersen Capital
People
HC Andersen Capital invited attendees to a discussion of Flügger group A/S quarterly financial statements on October 5th, 2026, featuring CEO Sune Schnack and CFO Lucas Eichild.
Reported by HC Andersen Capital
Customers & Market
HC Andersen Capital is hosting an investment seminar featuring CEO Jaroslaw Lipinski from CeMat A/S
Reported by HC Andersen Capital
Presence & Recognition
HC Andersen Capital is hosting an investment seminar on Danish stocks from 17 September to 2026
Reported by HC Andersen Capital
Legal & Regulatory
HC Andersen Capital reported that Pharma Equity Group A/S (PEG) announced that its partner Interpatium filed a lawsuit in Helsingør regarding the 12th of June 2026 theft of a vendetta claim.
Reported by HC Andersen Capital
Customers & Market
HC Andersen Capital reported that Scandinavian Medical Solutions (SMS) offert a larger order of upgrade packages to multiple systems to an existing customer in the USA.
Reported by HC Andersen Capital
Research & Knowledge
HC Andersen Capital published a research study focusing on the case in Napatech in Morgenbørs on 8/9/2026.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital updated its investment case and adjusted its valuation model for ExpreS2ion Biotechnologies' Q2 2026 report, including revised Phase II timing and cash position.
Reported by HC Andersen Capital
Presence & Recognition
HC Andersen Capital announced that Lars Højgård Hansen - CEO of INVISIO will give a presentation on Danish stocks at the investor seminar on Danish stocks on 13.30.
Reported by HC Andersen Capital
Research & Knowledge
HC Andersen Capital updated the Hafnia stock price to USD 0.5003, which is approximately NOK 4.65 per share, and the stock closed at NOK 80.15 on Friday, potentially falling below 6% from the morning close.
Reported by HC Andersen Capital
Research & Knowledge
HC Andersen Capital updated its investment case, recent market estimate adjustments, and a pipeline where the most significant catalysts for growth after 2030 are shifted forward, supported by analysts.
Reported by HC Andersen Capital
Research & Knowledge
HC Andersen Capital updated its investment case and model for ExpreS2ion Biotechnologies Q2 2026 and the revised timeline for phase II, along with the revised market implicit probability for success.
Reported by HC Andersen Capital
Presence & Recognition
HC Andersen Capital featured Tobias Friis as a guest speaker at the MORGENBØRS - 7/9-2026 event in Morgenbørs.
Reported by HC Andersen Capital
Capital & Finance
HC Andersen Capital updated its investment case for Lundbeck's H1 2026 financial year, reflecting the company's 2026 guidance, a pipeline with key drivers shifted forward, and a revised consensus pipeline contribution after 2030.
Reported by HC Andersen Capital
Strategy & Corporate Development
HC Andersen Capital CEO Tue Østergaard is advising that the Copenhagen Fund Exchange will be affected by a flight to Stockholm.
Reported by Tue Østergaard
Presence & Recognition
HC Andersen Capital CEO Frank Vang-Jensen participated in an interview with Nordea regarding how to act as an investor.
Reported by Tue Østergaard